No Data
Lukang Pharmaceutical: Summary of Lukang Pharmaceutical\'s 2024 Annual Report
Lukang Pharmaceutical: 2024 Annual Report of Lukang Pharmaceutical
2024 Annual Report of Lukang Pharmaceutical
Summary of the 2024 Annual Report of Lukang Pharmaceutical
Shandong Lukang Pharmaceutical (600789.SH): The net income for 2024 is 0.395 billion yuan, an increase of 60.30% year-on-year.
On March 21, Grizzly Investment announced that Shandong Lukang Pharmaceutical (600789.SH) released its annual report for 2024, showing revenue of 6.233 billion yuan for the reporting period, an increase of 1.41% year-on-year; net income attributable to shareholders of the listed company reached 0.395 billion yuan, reflecting a year-on-year growth of 60.30%; EPS was 0.44 yuan.
Shandong Lukang Pharmaceutical (600789.SH): Plans to increase registered capital to 18.92 million yuan for the electromechanical company.
On March 21, Gelonghui reported that Shandong Lukang Pharmaceutical (600789.SH) announced that the Electromechanical Company is a wholly-owned subsidiary of the company. In recent years, as the Electromechanical Company's Business scale has expanded, its registered capital has not matched that of similar enterprises in the Industry. To meet the company's Business expansion needs, it is proposed to use self-owned funds to increase the registered capital of the Electromechanical Company by 18.92 million yuan. After the capital increase is completed, the registered capital of the Electromechanical Company will increase from 11.08 million yuan to 30 million yuan.
Is The Market Rewarding Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
